title: [A comparative study on the serum and tissue 5-FU concentrations in patients with hepatocellular carcinoma after preoperative oral administration of UFT and 5'-DFUR].
abstract: UFT or 5'-DFUR was orally administered to the patients with hepatocellular carcinoma preoperatively and the concentrations of these drugs and 5-FU in the serum, liver tissue and cancer tissue obtained at the time of operation were measured. The unchanged 5'-DFUR was not detected in any of these samples. The concentration of 5-FU in cancer tissue was significantly higher in UFT treated group (0.409 microgram/g) than that in 5'-DFUR group (0.040 microgram/g). However, the 5-FU levels in the serum and noncancerous liver tissue were also higher than those in the patients with other organ cancers. Although UFT is a useful drug for the adjuvant chemotherapy of hepatocellular carcinoma, the dose was considered to be minimized to avoid the side effects since the activity of drug-metabolizing enzymes may be decreased in hepatocellular carcinoma complicated with liver cirrhosis.
authors.affiliation: Dept. of Surgery, Saga Medical School.
authors.forename: K
authors.initials: K
authors.lastname: Miyazaki
authors.forename: H
authors.initials: H
authors.lastname: Yakushiji
authors.forename: K
authors.initials: K
authors.lastname: Kitahara
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: E
authors.initials: E
authors.lastname: Sasatomi
authors.forename: N
authors.initials: N
authors.lastname: Tsutsumi
authors.forename: Y
authors.initials: Y
authors.lastname: Hirohashi
authors.forename: A
authors.initials: A
authors.lastname: Iwanaga
authors.forename: A
authors.initials: A
authors.lastname: Iyama
authors.forename: H
authors.initials: H
authors.lastname: Fukagawa
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000378:metabolism*; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000493:pharmacokinetics; D005472:Fluorouracil / Q000032:analysis* / Q000097:blood; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D005641:Tegafur / Q000008:administration & dosage / Q000493:pharmacokinetics; D014498:Uracil / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D005467:Floxuridine; D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil; C025034:doxifluridine